½ÃÇè°ú¸ñº° °øÁö»çÇ×

  • ½ÃÇè¾È³»
  • ½ÃÇè°ú¸ñº° °øÁö»çÇ×

2025³âµµ Á¦3ȸ Àü¹®¾à»ç ÀڰݽÃÇè °øÁö»çÇ×

- Á¤¸Æ¿µ¾ç -

1½ÃÇè³»¿ë ±¸¼º ¹× ½ÃÇè½Ã°£ (Àü °ú¸ñ °øÅë»çÇ×)

1)½ÃÇè³»¿ëÀº °øÅ뿵¿ª°ú Àü¹®¿µ¿ªÀ¸·Î ±¸¼ºµÊ.

  • °øÅ뿵¿ª : ÀÇÇÐÅë°è ¹× ÀǤý¾àÇÐ³í¹®ºñÆò
  • Àü¹®¿µ¿ª : Á¤¸Æ¿µ¾ç

2)½ÃÇè½Ã°£

  • ÃÑ ½ÃÇè½Ã°£ : ½ÃÇèÁغñ ¹× ¾È³», °øÁö½Ã°£ µîÀ» Æ÷ÇÔÇÏ¿© 180ºÐ(3½Ã°£).

2ÃâÁ¦À¯Çü ¹× ¹èÁ¡

1)°øÅ뿵¿ª(ÃÑ20Á¡) : °´°ü½Ä 20¹®Ç× (°¢ 1Á¡)

2)Àü¹®¿µ¿ª(ÃÑ80Á¡) : °´°ü½Ä 80¹®Ç× (°¢ 1Á¡)

  • ¾à¹°¿ä¹ýÀÇ ÀûÀý¼º °ËÅä
  • ¾à¹°¿ä¹ý °ü·Ã ¹®Á¦(drug-related problems) ÆÄ¾Ç ¹× ÇØ°á¹æ¾È Á¦½Ã
  • ȯÀÚ ¸ÂÃãÇü ¾à¹° ¼±Åà ¹× ¾à¹°¿ä¹ý °èȹ ¼ö¸³
  • ¾à¹°¿ä¹ýÀÇ Ä¡·áÈ¿°ú ¹× ¾à¹° ÀÌ»ó¹ÝÀÀ ¸ð´ÏÅ͸µ
  • ȯÀÚ ±³À°

3ÃâÁ¦¹üÀ§

1)°øÅ뿵¿ª ÃâÁ¦¹üÀ§ : ÀǾàÅë°èÀÇ ±âº»°³³ä ¹× À̸¦ Ȱ¿ëÇÑ ³í¹®Çؼ®°ú ºñÆò, ÀÓ»óÀû¿ë µî¿¡ °üÇÑ ¹®Ç×À¸·Î ÀÌ·ç¾îÁü.

  • ±Ù°Å±â¹ÝÀÇÇÐ(Evidence-Based Medicine) ¹× ±Ù°Å±â¹ÝÀÓ»ó½Ç¹«(Evidence-Based Clinical Practice, EBCP)ÀÇ ÀÌÇØ
  • ÀǾ๮ÇåÀÇ Á¾·ù ¹× Ư¡
  • ÀÓ»óÅë°èÀÇ ±âº» °³³ä
  • ³í¹®Çؼ®°ú ºñÆò, ÀÓ»óÀû¿ë

2)Àü¹®¿µ¿ª ÃâÁ¦¹üÀ§

  • ¿µ¾ç°ø±Þ ±¸¼º ¼ººÐÀÇ Æ¯Â¡
  • ȯÀÚ ¸ÂÃãÇü ¿µ¾çÁö¿ø°èȹ ¹× Á¶¼º ¼±ÅÃ
    • ¿µ¾ç»óÅ Æò°¡
    • ¿µ¾ç¿ä±¸·® »êÁ¤
    • ȯÀÚ¸ÂÃãÇü ¿µ¾çÁö¿ø°èȹ
      ¡á ¿µ¾ç°ø±Þ·® °è»ê
      ¡á Åõ¿©°æ·Î¼±Åà ¹× ÁÖÀÔ
  • Ư¼ö »óȲ ¹× ÁÖ¿ä Áúȯº° ¿µ¾çÁýÁßÄ¡·á
    • ½ÅºÎÀü, °£Áúȯ, À§Àå°üÁúȯ, ÆóÁúȯ, ½ÉÀåÁúȯ, ½Å°æ°èÁúȯ, ´ç´¢ ¹× ºñ¸¸ ½Ã ¿µ¾çÁö¿ø
    • ¼ö¼ú, ¾Ï, ÁßȯÀÚ/È­»óȯÀÚ¿¡¼­ÀÇ ¿µ¾çÁö¿ø
    • ÀÓºÎ, ½Å»ý¾Æ, ¹Ì¼÷¾Æ, ¼Ò¾Æ, ³ëÀÎȯÀÚÀÇ ¿µ¾çÁö¿ø
    • ÀçÅÿµ¾ç
  • ¿µ¾çÁö¿øÀÇ È¿°ú ¹× ÇÕº´Áõ ¸ð´ÏÅ͸µ
  • ¿µ¾ç¼Ò-¾à¹° »óÈ£ÀÛ¿ë* ¹× compatibility
    * Á¤¸Æ¿µ¾ç ÀÌ¿ÜÀÇ ÀϹÝÀûÀÎ ¿µ¾ç¼Ò-¾à¹° »óÈ£ÀÛ¿ëÀÌ Æ÷ÇÔµÊ
  • Á¤¸Æ¿µ¾ç °ø±Þ Á¦Ç°ÀÇ Æ¯Â¡ ¹× ¾ÈÁ¤¼º À̽´
    • »óǰÇü Á¤¸Æ¿µ¾ç¼ö¾×, Æ÷µµ´ç¼ö¾×, ¾Æ¹Ì³ë»ê¼ö¾×, Áö¹æÀ¯Á¦, ¹Ì·®¿ø¼Ò, ºñŸ¹Î µî

4Âü°í¹®Çå

1)Àü °ú¸ñ °øÅë Âü°í¹®Çå

°¡)¾à¹°Ä¡·áÇÐ °ü·Ã Âü°í¹®Çå

  • DiPiro JT, Yee GC, Haines ST, Nolin TD, Ellingrod VL, Posey LM, eds. Pharmacotherapy: A Pathophysiologic Approach. 12th ed., 2023.
  • Schwinghammer TL, Koehler JM, Borchert JS, Slain D, Park SK, eds. Pharmacotherapy Casebook: A Patient-Focused Approach. 12th ed., 2023.
  • Zeind CS, Carvalho MG, Cheng JW, Zaiken K, LaPointe T, eds. Applied Therapeutics: The Clinical Use of Drugs. 12th ed., 2023.
  • Chisholm-Burns MA, Schwinghammer TL, Malone PM, Kolesar JM, Bookstaver PB, Lee KC. Pharmacotherapy Principles & Practice. 6th ed., 2022.
  • Çѱ¹ÀÓ»ó¾àÇÐȸ. ¾à¹°Ä¡·áÇÐ Á¦6°³Á¤. ½ÅÀϺϽº. 2025

³ª)°øÅ뿵¿ª(ÀÇÇÐÅë°è ¹× ÀǤý¾àÇÐ³í¹®ºñÆò) °ü·Ã Âü°í¹®Çå

  • ¾à±¹½Ç¹«ºÐ°úȸ, ¾à·áÁ¤º¸ÇÐ, ½ÅÀϺϽº, 2021³â, Section III, Á¦ 9-13Àå, 16Àå
  • ¾à±¹½Ç¹«ºÐ°úȸ, ÀÓ»ó½Ç¹«¾àÇÐ, ½ÅÀϺϽº, 2024³â, 27Àå, 29Àå
  • Guyatt G, Rennie D, Meade MO & Cook DJ. Users¡¯ Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice. 3rd ed., New York, USA: McGraw Hill Education & The JAMA Network. 2015.
  • DiCenzo R, ed. Clinical Pharmacist's Guide to Biostatistics and Literature Evaluation. 2nd ed., Lenexa, KS, USA: American College of Clinical Pharmacy. 2015.
  • Browner WS, Thomas B Newman TB, Cummings SR. Designing Clinical Research. 5th ed. Wolters Kluwer. 2022.
  • Malone PM, Witt BA, Malone MJ, Peterson DM. Drug Information: A Guide for Pharmacists, 7th ed. McGraw Hill. 2022.
  • Canadian Medical Association Journal (CMAJ) evidence based medicine (EBM) series
    • Wyer PC, et al. Tips for learning and teaching evidence-based medicine: Introduction to the series. CMAJ 2004;171:347-8.
    • Barratt A, et al. Tips for learners of evidence-based medicine: 1. Relative risk reduction, absolute risk reduction and number needed to treat. CMAJ 2004;171:353-8.
    • Montoria VM, et al. Tips for learners of evidence-based medicine: 2. Measures of precision (confidence intervals). CMAJ 2005;171:611-5.

2)Àü¹®¿µ¿ª °ü·Ã Âü°í¹®Çå

°¡)The A.S.P.E.N. Adult nutrition support core curriculum, 3rd ed. 2017

³ª)ESPEN guidelines for adult parenteral nutrition

  • ESPEN guidelines on adult parenteral nutrition for specific diseases

´Ù)The A.S.P.E.N. Pediatric nutrition support core curriculum, 2nd ed. 2015

¶ó)ESPCHAN/ESPEN/ESPR/CSPEN guidelines on pediatric 2018

¸¶)ASPEN clinical guidelines

  • ASPEN guidelines on adult parenteral nutrition for specific diseases
  • Guidelines for parenteral nutrition in preterm infants: The American Society for Parenteral and Enteral Nutrition. JPEN 2023;47:830-858.
  • Parenteral Nutrition Compatibility and Stability: A Comprehensive Review. JPEN 2022;46(2):273-299
  • ASPEN Lipid Injectable Emulsion Safety Recommendations, Part 1: Background and Adult Considerations. NCP 2020;35(5): 769-782
  • ASPEN Consensus Recommendations for Refeeding Syndrome. Nutr Clin Pract. 2020;35:178- 195.
  • The Selection and Care of Central Venous Access Devices for Adult Home Parenteral Nutrition Administration. JPEN 2019;43(1):15-31
  • A.S.P.E.N. Parenteral Nutrition Safety Consensus Recommendations. JPEN 2014;38 (3):296-333
  • Parenteral Nutrition Ordering, Order Review, Compounding, Labeling, and Dispensing. JPEN 2014;38(3):334-377
  • A.S.P.E.N. Clinical Guidelines: Nutrition Support of Adult Patients With Hyperglycemia. JPEN 2013;37:23-36.